These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484 [TBL] [Abstract][Full Text] [Related]
6. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis. Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607 [TBL] [Abstract][Full Text] [Related]
7. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration. Park SS; Daftari I; Phillips T; Morse LS Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743 [TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Chan CK; Abraham P; Meyer CH; Kokame GT; Kaiser PK; Rauser ME; Gross JG; Nuthi AS; Lin SG; Daher NS Retina; 2010 Feb; 30(2):203-11. PubMed ID: 19952998 [TBL] [Abstract][Full Text] [Related]
9. Predictive value of spectral-domain optical coherence tomography features in assessment of visual prognosis in eyes with neovascular age-related macular degeneration treated with ranibizumab. Mathew R; Richardson M; Sivaprasad S Am J Ophthalmol; 2013 Apr; 155(4):720-6, 726.e1. PubMed ID: 23317653 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes. Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082 [TBL] [Abstract][Full Text] [Related]
11. A new grading system for retinal pigment epithelial tears. Sarraf D; Reddy S; Chiang A; Yu F; Jain A Retina; 2010; 30(7):1039-45. PubMed ID: 20458264 [TBL] [Abstract][Full Text] [Related]
12. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733 [TBL] [Abstract][Full Text] [Related]
13. Significant improvements in near vision, reading speed, central visual field and related quality of life after ranibizumab treatment of wet age-related macular degeneration. Frennesson C; Nilsson UL; Peebo BB; Nilsson SE Acta Ophthalmol; 2010 Jun; 88(4):420-5. PubMed ID: 19678811 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic and therapeutic challenges. Hatef E; Ibrahim M; Nguyen QD; Do DV; Davis MJ; Rezaei KA; Kovach JL Retina; 2011 Jun; 31(6):1218-23. PubMed ID: 21386757 [No Abstract] [Full Text] [Related]
15. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Bakall B; Folk JC; Boldt HC; Sohn EH; Stone EM; Russell SR; Mahajan VB Am J Ophthalmol; 2013 Jul; 156(1):15-22.e1. PubMed ID: 23706500 [TBL] [Abstract][Full Text] [Related]
16. Retinal pigment epithelium tear after intravitreal bevacizumab for exudative age-related macular degeneration. Spandau UH; Jonas JB Am J Ophthalmol; 2006 Dec; 142(6):1068-70. PubMed ID: 17157597 [TBL] [Abstract][Full Text] [Related]
17. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study. Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142 [TBL] [Abstract][Full Text] [Related]